Bilateral External Oblique Intercostal Plane Block in Post Operative Pain Management in Hepatectomy
Launched by SHERIF ALAA EMBABY · Feb 11, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method for managing pain after liver surgery (hepatectomy). It compares two pain relief techniques: a special nerve block called the Bilateral External Oblique Intercostal Plane Block (EOI block) and a system where patients can control their own pain medication, known as patient-controlled analgesia (PCA). The goal is to see which method is more effective at reducing pain and limiting the use of strong pain medications, especially since liver surgery can complicate how the body processes these drugs.
To be part of this study, participants should be between 18 and 65 years old and scheduled for hepatectomy surgery. They need to have a body weight that falls within a specific range (BMI of 18.5 to 30.0). However, some people won't be eligible, such as those with certain health conditions or those who have had other surgeries at the same time. If you join this trial, you can expect to receive one of the two pain relief methods after your surgery and be monitored closely to see how well it works for your recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 and ≤ 65 Years.
- • Both sexes.
- • Patients will be scheduled for hepatectomy surgery.
- • Body mass index (BMI) 18.5-30.0 /m 2 .
- Exclusion Criteria:
- • Extension of the surgical incision beyond coverage of T12 dermatome.
- • Prolonged time of surgery \> 5 hours.
- • Hepatectomy surgery combined with another organ resection.
- • Patients with hypersensitivity to local anesthetics.
- • History of psychiatric problems.
- • Recent history of analgesic drugs including opioid abuse or addiction.
- • Coagulopathy (International normalized ratio \[INR\] \> 1.4).
- • Localized infection at the block site.
- • Morbidly obese patients.
About Sherif Alaa Embaby
Sherif Alaa Embaby is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a focus on ethical practices and regulatory compliance, the organization collaborates with healthcare professionals and institutions to design and execute rigorous clinical trials across various therapeutic areas. Leveraging extensive expertise in trial management and a patient-centric approach, Sherif Alaa Embaby aims to contribute valuable insights to the medical community while ensuring the safety and welfare of trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported